Susquehanna International Group, LLP Molecular Partners Ag Transaction History

Susquehanna International Group, LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$3.53 - $4.62 $13,968 - $18,281	-3,957 Reduced 23.87%	12,618 $52,000
Q3 2023 Nov 14, 2023	SELL	$4.14 - $6.69 $51,741 - $83,611	-12,498 Reduced 42.99%	16,575 $68,000
Q2 2023 Aug 11, 2023	SELL	$5.81 - $6.93 $15,007 - $17,900	-2,583 Reduced 8.16%	29,073 $180,000
Q1 2023 May 16, 2023	SELL	$5.8 - $7.32 $11,623 - $14,669	-2,004 Reduced 5.95%	31,656 $191,000
Q4 2022 Feb 14, 2023	BUY	$6.03 - $7.08 $202,969 - $238,312	33,660 New	33,660 $220,000

3.58M

Ticker MOLN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,514,000
Market Cap $114M
Description
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.